Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

NCT ID: NCT00003215

Last Updated: 2012-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-04-30
• Study Completion Date: 2004-03-31

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells. It is not known whether receiving standard combination chemotherapy alone is more effective than receiving multiple combination chemotherapy plus peripheral stem cell transplantation for aggressive non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing giving different combination chemotherapy regimens together with peripheral stem cell transplantation to see how well they work in treating patients with newly diagnosed aggressive non-Hodgkin's lymphoma.

Detailed Description

OBJECTIVES:

• Compare the efficacy of sequential high-dose chemotherapy and autologous peripheral blood stem cell transplantation with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed aggressive non-Hodgkin's lymphoma and poor prognostic factors.
• Compare the toxic effects of these 2 regimens in these patients.
• Compare the response rates and overall survival of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.

• Arm I: Patients receive standard chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Patients receive cyclophosphamide IV over 30 minutes, doxorubicin IV, and vincristine IV on day 1. Patients receive oral prednisone daily on days 1-5. Treatment repeats every 21 days for 6-8 courses. Patients with bulky disease at diagnosis or residual disease after chemotherapy receive radiotherapy 30-60 days after initiation of the last course of CHOP.
• Arm II: Patients receive 5 regimens of chemotherapy administered in sequence.

• Regimen A : Patients receive CHOP as in Arm I.
• Regimen B: Three weeks after starting regimen A, patients receive high-dose cyclophosphamide IV over 24 hours on day 1. Patients without initial bone marrow involvement receive filgrastim (G-CSF) subcutaneously (SC) daily beginning on day 3 and continuing until autologous peripheral blood stem cells (PBSC) are harvested. PBSC are harvested on days 13-15 or when blood counts recover. Patients with initial bone marrow involvement do not undergo harvest of PBSC at this time, but receive G-CSF SC daily.
• Regimen C: Two to three weeks after high-dose cyclophosphamide, patients receive vincristine IV and high-dose methotrexate IV over 6 hours on day 2. Patients receive leucovorin calcium IV every 6 hours on days 3-5 beginning 24 hours after initiation of the methotrexate infusion.
• Regimen D: Within 1-2 weeks after the administration of methotrexate in regimen C, patients receive methylprednisolone IV followed 6 hours later by high-dose etoposide IV over 10 hours on day 1. Patients receive methylprednisolone IV on day 2. Patients without initial bone marrow involvement receive G-CSF SC daily beginning on day 3 and continuing until blood counts recover. Patients with initial bone marrow involvement receive G-CSF SC daily until autologous PBSC are harvested. PBSC are harvested on days 10-14 or when blood counts recover.
• Regimen E: Myeloablative therapy and autologous PBSC transplantation begin 16-40 days after the administration of etoposide. Patients receive mitoxantrone IV over 1 hour every 2 hours for 3 doses on day 2 and melphalan IV over 30 minutes on day 5. PBSC are reinfused on day 6 beginning at least 24 hours after the administration of melphalan. Patients receive G-CSF SC or by continuous infusion beginning on day 7.

Patients with bulky disease at diagnosis or residual disease after chemotherapy receive radiotherapy 30-100 days after PBSC transplantation.

Patients at high risk of developing CNS disease receive prophylactic intrathecal chemotherapy. Patients may receive cytarabine, methotrexate, and hydrocortisone or methotrexate and hydrocortisone every 1-2 weeks for 6 courses.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 400 patients will be accrued for this study within 4-5 years.

Conditions

Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Primary Study Purpose: TREATMENT

Interventions

filgrastim

Intervention Type: BIOLOGICAL

CHOP regimen

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

cytarabine

Intervention Type: DRUG

doxorubicin hydrochloride

Intervention Type: DRUG

etoposide

Intervention Type: DRUG

leucovorin calcium

Intervention Type: DRUG

melphalan

Intervention Type: DRUG

methotrexate

Intervention Type: DRUG

methylprednisolone

Intervention Type: DRUG

mitoxantrone hydrochloride

Intervention Type: DRUG

prednisone

Intervention Type: DRUG

therapeutic hydrocortisone

Intervention Type: DRUG

vincristine sulfate

Intervention Type: DRUG

bone marrow ablation with stem cell support

Intervention Type: PROCEDURE

peripheral blood stem cell transplantation

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL)

• Diffuse large B-cell lymphoma
• Primary mediastinal large B-cell lymphoma
• Anaplastic large cell lymphoma (B-cell, T-cell, or null-cell type)
• At least two of the following risk factors:

• Stage III or IV
• LDH greater than upper limit of normal (ULN)
• ECOG 2, 3, or 4
• No CNS involvement

PATIENT CHARACTERISTICS:

Age:

• 18 to 60

Performance status:

• See Disease Characteristics
• ECOG 0-4

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• No hepatitis B or C
• AST or ALT no greater than 2 times ULN*
• Bilirubin no greater than 2.34 mg/dL* NOTE: *Unless due to tumor involvement

Renal:

• Creatinine clearance at least 60 mL/min (unless due to tumor involvement)

Cardiovascular:

• No significant heart failure
• LVEF normal
• No active angina pectoris
• No myocardial infarction within the past 6 months
• No major ventricular arrhythmia

Pulmonary:

• No significant lung disorder

Other:

• HIV negative
• No severe active acute or chronic infection
• No severe psychoses
• No prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or nonmelanomatous skin cancer
• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for NHL (except emergency therapy, but no more than 1 course of standard chemotherapy)

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior radiotherapy for NHL (except emergency therapy of no greater than 600 cGy radiation)
• No concurrent prophylactic radiotherapy to the brain

Surgery:

• Not specified

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Swiss Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel C. Betticher, MD

Role: STUDY_CHAIR

Insel Gruppe AG, University Hospital Bern

Locations

Allgemeines Krankenhaus der Stadt Wien

Vienna, , Austria

Dr. Horst-Schmidt-Kliniken

Wiesbaden, , Germany

Saint Savvas Cancer Hospital of Athens

Athens, , Greece

European Institute of Oncology

Milan, , Italy

Universitatsspital-Basel

Basel, , Switzerland

Oncology Institute of Southern Switzerland

Bellinzona, , Switzerland

Inselspital, Bern

Bern, , Switzerland

Ratisches Kantons und Regionalspital

Chur, , Switzerland

Hopital Cantonal Universitaire de Geneve

Collonge-Bellerive, , Switzerland

Centre Hospitalier Universitaire Vaudois

Lausanne, , Switzerland

Kantonsspital - St. Gallen

Sankt Gallen, , Switzerland

Klinik Hirslanden

Zurich, , Switzerland

Countries

Austria; Germany; Greece; Italy; Switzerland

References

Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006 Oct;17(10):1546-52. doi: 10.1093/annonc/mdl153. Epub 2006 Aug 3.

Reference Type: RESULT

PMID: 16888080 (View on PubMed)

Other Identifiers

SWS-SAKK-38/97

Identifier Type: -

Identifier Source: secondary_id

EU-97037

Identifier Type: -

Identifier Source: secondary_id

SAKK 38/97

Identifier Type: -

Identifier Source: org_study_id